UK MHRA Policy Update: CE Certificates Under EU MDR Recognised Indefinitely in Great Britain, UKCA Route Remains Available
Nov 10, 2026
October - The UK Parliament and MHRA have confirmed a key regulatory policy: dental prostheses with valid CE certification under EU MDR will be accepted on the Great Britain market on an indefinite basis, while the UKCA marking pathway remains available as a parallel option. For dental laboratories exporting to the UK, MDR CE stays the core market access credential, though manufacturers must maintain full UDI compliance and post-market surveillance (PMS).
Following Brexit, the recognition of CE-marked medical devices in Britain had been governed by time-limited transitional arrangements, previously scheduled to expire no later than June 2030. This parliamentary decision converts the acceptance of MDR CE devices from a temporary transition rule into a long-standing regime. As long as the CE certificate remains valid, compliant MDR dental prostheses can be placed on the British market without duplicate UKCA conformity assessment, cutting redundant certification costs for cross-border dental OEMs.
The UKCA route is not withdrawn and remains an optional alternative pathway. Manufacturers may choose either MDR CE or UKCA for market access. Importantly, MHRA's market surveillance authority applies equally to both routes. Mandatory requirements including UDI labelling and registration, technical documentation, ongoing PMS, adverse incident reporting and recall preparedness must all be maintained. Even with a valid CE certificate, products may be suspended or penalised if PMS records, UDI data or incident reporting fail to meet MHRA standards.
This ruling brings long-term regulatory certainty to the UK dental prosthetics import market, a major destination for outsourced dental restorations. Chinese dental OEM labs can continue leveraging existing MDR CE certification for British orders without building a separate UK-only certification workflow. Compliance focus shifts from initial certification to sustained system management: robust UDI records, regular PMS reports and clear accountability for UK-based importers or distributors.
Industry analysts note the ruling removes a major regulatory risk for exporters targeting the UK. It does not signal lighter oversight; MHRA will strengthen post-market audits. Overseas dental labs need to embed UDI and PMS routines into their standard operation to avoid non-compliance hold-ups, even with valid CE certificates.







